202 related articles for article (PubMed ID: 36102312)
1. Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis.
Kayali S; Pasta A; Plaz Torres MC; Jaffe A; Strazzabosco M; Marenco S; Giannini EG
Liver Int; 2023 Jan; 43(1):8-17. PubMed ID: 36102312
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitor therapy for malignant tumors in liver transplantation recipients: A systematic review of the literature.
Zhang P; Zhu G; Li L; Lai G; Wang Z; Sun C; Xia W; Wu L
Transplant Rev (Orlando); 2022 Dec; 36(4):100712. PubMed ID: 35870411
[TBL] [Abstract][Full Text] [Related]
3. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
Kumar V; Shinagare AB; Rennke HG; Ghai S; Lorch JH; Ott PA; Rahma OE
Oncologist; 2020 Jun; 25(6):505-514. PubMed ID: 32043699
[TBL] [Abstract][Full Text] [Related]
4. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
5. Optimizing the Safe Washout Period for Liver Transplantation Following Immune Checkpoint Inhibitors with Atezolizumab, Nivolumab, or Pembrolizumab.
Kuo FC; Chen CY; Lin NC; Liu C; Hsia CY; Loong CC
Transplant Proc; 2023 May; 55(4):878-883. PubMed ID: 37127513
[TBL] [Abstract][Full Text] [Related]
6. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.
Ziogas IA; Evangeliou AP; Giannis D; Hayat MH; Mylonas KS; Tohme S; Geller DA; Elias N; Goyal L; Tsoulfas G
Oncologist; 2021 Jun; 26(6):e1036-e1049. PubMed ID: 33314549
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitors in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Case Report and Literature Review.
Qiu J; Tang W; Du C
Curr Cancer Drug Targets; 2020; 20(9):720-727. PubMed ID: 32433005
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy and transplantation for hepatocellular carcinoma.
Tabrizian P; Abdelrahim M; Schwartz M
J Hepatol; 2024 May; 80(5):822-825. PubMed ID: 38253289
[TBL] [Abstract][Full Text] [Related]
9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
10. Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy.
Dehghan Y; Schnickel GT; Hosseini M; Burgoyne AM; Ajmera VH; Morris GP; Mendler MH; Parekh JR; Abushamat F; Vodkin I; Kono Y
Clin J Gastroenterol; 2021 Dec; 14(6):1718-1724. PubMed ID: 34643885
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single-center analysis.
Owoyemi I; Vaughan LE; Costello CM; Thongprayoon C; Markovic SN; Herrmann J; Otley CC; Taner T; Mangold AR; Leung N; Herrmann SM; Kukla A
Cancer; 2020 Nov; 126(21):4780-4787. PubMed ID: 32786022
[TBL] [Abstract][Full Text] [Related]
12. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
[TBL] [Abstract][Full Text] [Related]
13. A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant.
Murakami N; Mulvaney P; Danesh M; Abudayyeh A; Diab A; Abdel-Wahab N; Abdelrahim M; Khairallah P; Shirazian S; Kukla A; Owoyemi IO; Alhamad T; Husami S; Menon M; Santeusanio A; Blosser CD; Zuniga SC; Soler MJ; Moreso F; Mithani Z; Ortiz-Melo D; Jaimes EA; Gutgarts V; Lum E; Danovitch GM; Cardarelli F; Drews RE; Bassil C; Swank JL; Westphal S; Mannon RB; Shirai K; Kitchlu A; Ong S; Machado SM; Mothi SS; Ott PA; Rahma O; Hodi FS; Sise ME; Gupta S; Leaf DE; Devoe CE; Wanchoo R; Nair VV; Schmults CD; Hanna GJ; Sprangers B; Riella LV; Jhaveri KD;
Kidney Int; 2021 Jul; 100(1):196-205. PubMed ID: 33359528
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant programmed cell death 1 inhibitor before liver transplantation for HCC is not associated with increased graft loss.
Wang T; Chen Z; Liu Y; Jia Y; Ju W; Chen M; Zhao Q; Wang D; Guo Z; Tang Y; He X
Liver Transpl; 2023 Jun; 29(6):598-606. PubMed ID: 36747346
[TBL] [Abstract][Full Text] [Related]
15. Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma: A multicenter, retrospective cohort study.
Guo Z; Liu Y; Ling Q; Xu L; Wang T; Zhu J; Lin Y; Lu X; Qu W; Zhang F; Zhu Z; Zhang J; Jia Z; Zeng P; Wang W; Sun Q; Luo Q; Hu Z; Zheng Z; Jia Y; Li J; Zheng Y; Wang M; Wang S; Han Z; Yu S; Li C; Zhang S; Xiong J; Deng F; Liu Y; Chen H; Wang Y; Li L; Liang W; Schlegel A; Nashan B; Liu C; Zheng S; He X
Am J Transplant; 2024 Apr; ():. PubMed ID: 38642712
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?
Jiang J; Huang H; Chen R; Lin Y; Ling Q
Front Immunol; 2023; 14():1092401. PubMed ID: 36875077
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review.
Qiao ZY; Zhang ZJ; Lv ZC; Tong H; Xi ZF; Wu HX; Chen XS; Xia L; Feng H; Zhang JJ; Xia Q
Front Immunol; 2021; 12():653437. PubMed ID: 34349755
[TBL] [Abstract][Full Text] [Related]
18. Transplant rejections associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature review.
Nguyen LS; Ortuno S; Lebrun-Vignes B; Johnson DB; Moslehi JJ; Hertig A; Salem JE
Eur J Cancer; 2021 May; 148():36-47. PubMed ID: 33721705
[TBL] [Abstract][Full Text] [Related]
19. An analysis report on the application of immune checkpoint inhibitors after liver transplantation.
Xie M; Dang ZP; Sun XG; Zhang B; Zhang Q; Tian QJ; Cai JZ; Rao W
Ther Adv Chronic Dis; 2022; 13():20406223221099334. PubMed ID: 35620187
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors in liver transplant: a case series.
Rudolph M; Shah SA; Quillin R; Lemon K; Olowokure O; Latif T; Sohal D
J Gastrointest Oncol; 2023 Apr; 14(2):1141-1148. PubMed ID: 37201081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
